Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 6:31 PM ET

Date/Time Source News Release
05/21/2025 08:55 AM EDT GlobeNewswire Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
05/16/2025 04:15 PM EDT GlobeNewswire Silo Pharma Announces Closing of $2 Million Public Offering
05/14/2025 04:07 PM EDT GlobeNewswire Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
05/14/2025 08:40 AM EDT GlobeNewswire Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
04/30/2025 08:11 AM EDT GlobeNewswire Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
04/28/2025 07:50 AM EDT GlobeNewswire Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
03/26/2025 08:40 AM EDT GlobeNewswire Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
02/26/2025 01:30 PM EST GlobeNewswire Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
02/18/2025 08:50 AM EST GlobeNewswire Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
02/11/2025 07:45 AM EST GlobeNewswire Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
Page

Additional News

As of June 4, 2025 • 6:31 PM ET

Date/Time Source News Release
05/21/2025 09:55 AM EDT InvestorWire InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with Nasal Spray Device Study for SPC-15
05/21/2025 09:46 AM EDT SeekingAlpha Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug
05/19/2025 09:05 AM EDT InvestorWire InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Closes $2 Million Public Offering of Shares and Warrants
05/16/2025 09:15 AM EDT InvestorWire InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Prices $2 Million Public Offering of Common Stock and Warrants
05/15/2025 09:25 AM EDT InvestorWire InvestorkNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
05/15/2025 09:25 AM EDT InvestorWire InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
05/15/2025 09:24 AM EDT SeekingAlpha Silo Pharma announces pricing of $2 million public offering
05/14/2025 10:05 AM EDT InvestorWire InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
05/11/2025 05:30 AM EDT US Earnings Reports Expected earnings - Silo Pharma Inc.
04/30/2025 09:35 AM EDT InvestorBrandNetwork BioMedNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant 
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.